S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.05 CNY -6.83% Market Closed
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Income Statement

Earnings Waterfall
Shanghai MicuRx Pharmaceutical Co Ltd

Revenue
81.7m CNY
Cost of Revenue
-14.9m CNY
Gross Profit
66.8m CNY
Operating Expenses
-471.1m CNY
Operating Income
-404.3m CNY
Other Expenses
6.1m CNY
Net Income
-398.1m CNY

Income Statement
Shanghai MicuRx Pharmaceutical Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Sep-2023 Dec-2023 Mar-2024
Revenue
Revenue
8
N/A
18
+140%
28
+53%
37
+32%
48
+30%
55
+14%
57
+4%
91
+60%
82
-10%
Gross Profit
Cost of Revenue
(1)
(2)
(4)
(7)
(9)
(11)
(11)
(17)
(15)
Gross Profit
7
N/A
16
+134%
24
+47%
30
+27%
39
+30%
44
+12%
46
+5%
74
+61%
67
-10%
Operating Income
Operating Expenses
(270)
(288)
(289)
(323)
(271)
(284)
(277)
(510)
(471)
Selling, General & Administrative
(113)
(134)
(134)
(144)
(132)
(148)
(117)
(162)
(141)
Research & Development
(151)
(159)
(160)
(180)
(148)
(161)
(186)
(334)
(333)
Depreciation & Amortization
(12)
(0)
0
0
(16)
0
0
(15)
0
Other Operating Expenses
5
6
6
2
24
25
25
0
4
Operating Income
(264)
N/A
(271)
-3%
(265)
+2%
(292)
-10%
(232)
+21%
(240)
-3%
(231)
+4%
(436)
-89%
(404)
+7%
Pre-Tax Income
Interest Income Expense
7
4
1
9
8
14
10
25
12
Non-Reccuring Items
(0)
0
0
0
0
0
(0)
0
0
Total Other Income
30
25
16
8
3
0
(1)
(4)
(0)
Pre-Tax Income
(226)
N/A
(242)
-7%
(247)
-2%
(275)
-11%
(220)
+20%
(225)
-2%
(222)
+2%
(415)
-87%
(392)
+6%
Net Income
Tax Provision
(0)
0
(0)
(0)
(0)
0
(0)
(6)
0
Income from Continuing Operations
(226)
(242)
(247)
(275)
(220)
(225)
(222)
(421)
(398)
Net Income (Common)
(226)
N/A
(242)
-7%
(247)
-2%
(275)
-11%
(220)
+20%
(225)
-2%
(222)
+2%
(421)
-90%
(398)
+5%
EPS (Diluted)
-0.35
N/A
-0.37
-6%
-0.38
-3%
-0.42
-11%
-0.34
+19%
-0.34
N/A
-0.34
N/A
-0.64
-88%
-0.61
+5%

See Also

Discover More